Acadia’s Nuplazid Needs Another Study For Alzheimer’s Psychosis, US FDA Panel Says

 
• By Sue Sutter

Advisory committee members cited a litany of shortfalls with efficacy data from two existing studies and say a new Phase III trial is needed in a large, ethnically and racially diverse population of Alzheimer’s disease psychosis patients.

Truck blocking road
For Nuplazid to add an indication in Alzheimer's psychosis, there is no way around conducting another study, an FDA panel member said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers